Top Bulls Reasons To Buy — Vote below!

90%
agree
Strong on flu vaccines
100%
agree
Swine Flu Winner
100%
agree
Cancer vaccine

Add a New Bulls Reason

Company: GlaxoSmithKline (GSK)
Current price:
Headline: (100 character max)
Analysis:
Cancel
90%
agree
22 votes

  Strong on flu vaccines

The development of a vaccine for a flu pandemic at this point before the outbreak occurs ensures that GlaxoSmithKline will be ahead in capturing market share. It has already received commitments from some governments to purchase the vaccine if the flu strikes.

(100 character max) Cancel
100%
agree
4 votes

  Swine Flu Winner

The swine flu scare that’s hit Europe, North America, Central America and Asia so far this week has been responsible for over eighty deaths. That’s especially bad if you’re down in Mexico, where the strain has hit the hardest. Here in the U.S., up in Canada, Spain, France, Hong Kong, and New Zealand, the situation seems to be much more in hand despite official worries that the world is likely to see many more cases before this is over.

But in hand or not, the pharmaceutical sector is making out on this one. As everything from heightened levels of caution to full out fear and panic rises among governments and citizens alike, many investors are looking at the situation from a completely different angle…

… Which is exactly why Gilead Sciences Inc. (Nasdaq: GILD), GlaxoSmithKline (Nasdaq: GSK), Switzerland-based Roche and like-minded companies are doing as well as they are this morning.

Sure, the major indexes are all back up after a rough start this morning, but how many other stocks can claim they more than doubles?

Novavax (Nasdaq: NVAX) can for one, since savvy investors know that its experimental vaccine for one strain of avian influenza produced a strong immune response in human test cases so far. And Novavax says that utilizing its specialized technology, it could produce a suitable vaccine for this emerging problem in double-time.


If officials are right that things will get worse before they’ll get better, you can better believe that those stocks will continue to rise.

(100 character max) Cancel
100%
agree
3 votes

  Cancer vaccine

GlaxoSmithKline’s new vaccine for HPV, Cervarix, could become a major player in the market once it is approved, likely in early 2008. Demand for this vaccine, which would prevent the virus that causes cervical cancer, will likely be substantial.

(100 character max) Cancel
0%
agree
0 votes

  Good at gaming the patent expiration system

GlaxoSmithKline’s ability to effectively plan “life-cycle management” through reformulating drugs has allowed it to protect Coreg from generic competition. This technique will continue to help it capture more revenue from its research investments.

(100 character max) Cancel
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki